ClinicalTrials.gg
RecruitingNCT06816927GIANTUpdated Sep 17, 2026

Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab

A Phase 2 interventional study of Nivolumab and Relatlimab in Newly Diagnosed Glioblastoma, sponsored by Duke University. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Duke University · Phase 2, Interventional, and Treatment

How we know · 7 judgments

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing nivolumab in Glioblastoma — 3 open to participants now, 11 under way, none of them phase 3. Nivolumab · Glioblastoma.

Planned enrollment
6th of 20
92 · median 36
Started
2025
with 1 other
Phase 2
12 of 20
2 open now
Primary completion
2029-06
later than 10 of 10 live
Registered
19th of 20
by date
Lead sponsor
1 of 20
Duke University

Among the 20 studies testing nivolumab in Glioblastoma, this one is the 6th largest by planned enrollment, is one of 2 that started in 2025, is one of 12 in phase 2, reaches primary completion later than 10 of the 10 other live ones, and was the 19th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

3 of the 20 studies testing nivolumab in Glioblastoma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing nivolumab in Glioblastoma, or all of them as a file.
02

Study summary

GIANT is an open-label, multi-center, randomized, perioperative (neoadjuvant followed by adjuvant), phase 2 trial with a safety lead-in phase to investigate the feasibility, safety and tolerability, and establish the biological activity of nivolumab with or without relatlimab in patients with isocitrate dehydrogenase (IDH) wildtype newly diagnosed glioblastoma (ndGBM).

Read the detailed description

Hypotheses for GIANT: A perioperative trial of nivolumab with or without relatlimab in patients with ndGBM is feasible and safe and that we will be able to evaluate the biological effect (pharmacodynamics [PD]) of nivolumab monotherapy and in combination with relatlimab in this setting and determine whether there is sufficient biological activity in patients with GBM to warrant further development.

Patients with a ndGBM and those with a previous diagnosis of GBM who have not received prior radiation (RT) or systemic therapy will have histological confirmation of diagnosis either by on study stereotactic biopsy or from an archival tissue. Cohorts of 6 patients will be accrued to receive nivolumab and relatlimab combined with RT and TMZ in the safety lead-in portion. Once determined safe, the randomized portion of the study will commence and patients will be randomized to one of two arms for neoadjuvant treatment prior to surgical resection of their tumor using an unbalanced 1:3 treatment allocation: Arm 1 - nivolumab alone or Arm 2 - nivolumab and relatlimab (combination formulation). After tumor resection, all patients will undergo Part 1 adjuvant treatment and receive RT and temozolomide (TMZ) (TMZ will be omitted in MGMT unmethylated patients), in combination with nivolumab and relatlimab. Afterwards, patients will undergo Part 2 adjuvant treatment, wherein they will receive TMZ in combination with nivolumab and relatlimab until progression or discontinuation criteria are met. All patients will be followed for 2 years after the last patients has been registered.

Primary Objectives:

  1. Stage 1 - Safety Lead-In: To assess the safety of concurrently administering nivolumab, relatlimab, RT, with or without TMZ during Part 1 of the Adjuvant Treatment phase in ndGBM patients, with a specific go-no go focus on MGMT methylated patients receiving TMZ
  2. Stage 2 - Randomized Phase 2: To assess the feasibility of undertaking a peri-operative study involving administration of nivolumab with or without relatlimab in patients with ndGBM
  3. To establish the biological activity of nivolumab administered with or without relatlimab in patients with ndGBM, by demonstrating the presence of tumor infiltrating lymphocytes (TILs) in the resected tumor

Secondary Objectives:

  1. To describe the toxicity of nivolumab administered with or without relatlimab during the neoadjuvant phase in patients with ndGBM following tumor biopsy, and prior to surgical resection of their tumor
  2. To assess the safety of planned craniotomy and tumor resection performed after biopsy and neoadjuvant treatment with nivolumab administered with or without relatlimab in patients with ndGBM
  3. To determine the toxicity of nivolumab administered with relatlimab during the adjuvant phase, following surgical resection of their tumor in patients with ndGBM To assess the pharmacokinetics (PK) of nivolumab administered with or without relatlimab during the neoadjuvant phase following biopsy, and prior to tumor resection for patients with ndGBM
  4. To estimate the radiological response rate of nivolumab administered with or without relatlimab in ndGBM
  5. To describe survival of patients who have been assigned (as in the Stage 1 safety lead-in) or randomized (Stage 2) to receive neoadjuvant nivolumab administered with or without relatlimab.

After their biopsy or confirmation of diagnosis from the archival tissue, patients will be randomized in the Neoadjuvant Treatment stage to receive one cycle of either nivolumab alone (Arm 1) or the combination of nivolumab and relatlimab (Arm 2). Within 14 (±3) days of day 1 of neoadjuvant treatment all patients registered in Stages 1 and 2 will undergo tumor resection and placement of Ommaya reservoir. After surgery, patients will enter the Part 1 Adjuvant Treatment phase and will receive RT and TMZ chemotherapy in combination with nivolumab and relatlimab. After the last dose of treatment in Part 1 Adjuvant Treatment, patients will begin the Part 2 Adjuvant Treatment phase and will receive 6 cycles of TMZ in combination with nivolumab and relatlimab. Patients that complete the treatment (i.e., complete 12 cycles of nivolumab and relatlimab with or without TMZ in the Part 2 Adjuvant Treatment Phase) or that discontinue treatment for any reason will have an End of Treatment visit and a Safety Follow-up visit 135 days after the End of Treatment visit

03

Conditions studied

  • Newly Diagnosed Glioblastoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed approved by the IRB
  2. Adults ≥ 18 years of age
  3. Patients with either:

    • A newly suspected diagnosis of GBM based on MRI
    • A previous diagnosis of GBM and who have not received prior RT or systemic therapy for their brain tumor
  4. Patients who in the opinion of the treating neurosurgeon require resection
  5. Patient is willing to undergo planned surgical procedures
  6. Patient agrees to make biospecimens that will be prospectively collected (after date of consent) available for research
  7. Patients who have undergone a diagnostic or open surgical procedure prior to enrolling in this study:

    • If adequate archival tissue, defined as at least 3 blocks, is readily available, there is clear documentation of its availability, and the patient must consents to provide that tissue, the patient does not need to undergo another biopsy prior to, or on study, in order to be eligible for this trial
    • If archival tissue is sufficient as described above, patient must have either residual enhancing disease requiring resection, or molecularly confirmed GBM with a clear clinical indication for additional resection, as determined by the country PI (or delegate) and the designated trial surgeon.
    • If archival tissue is insufficient, or if the patient previously underwent a needle biopsy and there is no clear documentation of tissue availability, and the patient wishes to enroll, the patient must agree to undergo a repeat biopsy as part of this study prior to Screening.
  8. Hematological function as follows:

    • ≥ 1.5 x 109/L
    • count ≥ 100 x 109/L
    • > 90 g/L
    • (PT) or partial thromboplastin time (PTT) \< 1.5 x (ULN)
  9. Renal function as follows:

    • Serum creatinine ≤ 1.5 x ULN or calculated ≥ 40 ml/min using the Cockcroft-Gault formula (Appendix 1)
  10. Hepatic function as follows:

    • Total ≤ 1.5 x ULN (Exception: Patient has known or suspected Gilbert's Syndrome for which additional lab testing of direct and/or indirect bilirubin supports this diagnosis. In these instances, a total bilirubin of ≤ 3.0 x ULN is acceptable)
    • Alkaline phosphatase (ALP) ≤ 2.5 x ULN
    • (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN
    • Serum albumin ≥ 25 g/L
  11. Eastern Co-operative Oncology Group () performance status of 0-1 (Appendix 2)
  12. of at least 12 months
  13. Negative (HIV) test at Screening
  14. Negative surface antigen (HbsAg) test at Screening or positive test followed by a negative hepatitis B virus (HBV) DNA test at Screening
  15. Negative antibody (anti-HCV) test at Screening or positive test followed by a negative HCV RNA test at Screening
  16. Able to undergo brain MRI with and without contrast
  17. People of must agree to use a highly effective method (with a failure rate of \< 1%) during study treatment and for at least 6 months following the last dose of study drug and agree not to donate eggs (ova, oocytes) for the purpose of reproduction for the same time period. Acceptable methods of contraception are:

    • Combined estrogen and progestin containing hormonal contraception associated with inhibition of ovulation given orally, intravaginally, or transdermally
    • Progestin-only hormonal contraception associated with inhibition of ovulation given orally, by injection, or by implant
    • Intrauterine device: Intrauterine hormone-releasing system
    • Bilateral tubal occlusion
    • Vasectomised partner
    • Sexual abstinence: Considered a highly effective method only if defined as refraining from heterosexual intercourse during an entire period of risk associated with the study treatment. The reliability of sexual abstinence needs will be evaluated in relation to the duration of the study and to the usual lifestyle of the patient Note: People are considered and not of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least 6 weeks ago. In the case of oophorectomy alone, only when the reproductive status of the person has been confirmed by follow-up hormone level assessment are they considered not of childbearing potential.
  18. Sexually active patients that are able to produce a sperm, must use a condom during intercourse and must agree to refrain from sperm donation, from registration on the study until 3 months after the last dose of treatment
  19. People of childbearing potential must have a negative highly sensitive serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) at the time of screening and within 48 hours of starting the study drug(s)
  20. Ability to adhere to the study visit schedule and all protocol requirements

Exclusion criteria

Exclusion Criteria:

  1. Tumors where a gross total resection is not considered feasible by the treating neurosurgeon
  2. Tumor involves cerebellum, brainstem, or deep basal ganglia
  3. Patients who require urgent resection for mass effect, cerebral edema, or hydrocephalus in the opinion of the treating neurosurgeon
  4. Patients with to MRI or unwilling to undergo MRI
  5. History of CNS bleeding as defined by stroke within 6 months prior to registration
  6. Contraindication to surgery
  7. Treatment with medications Note: Low-dose (≤ 2 mg/day dexamethasone or equivalent) for tumor-associated edema is permitted. Patients who require corticosteroids > 2mg/day dexamethasone (or equivalent) for acute emergencies during the screening window will be eligible, if the corticosteroid dosing reduces to ≤ 2 mg/day dexamethasone (or equivalent) at least one day prior to the initial trial-mandated .
  8. Active disease or immune deficiency including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis
  9. Active tuberculosis
  10. Patient has had a previous SARS-CoV-2 infection either suspected or confirmed within 4 weeks prior to screening. Acute symptoms must have resolved and based on treating physician's assessment, there are no sequelae that would place the patient at a higher risk of receiving trial treatment
  11. Evidence of acute intracranial/intra-tumoral hemorrhage, which requires urgent intervention
  12. Severe infection within 4 weeks prior to registration
  13. Treatment with a live, attenuated vaccine within 4 weeks prior to registration, or anticipation of need for such a vaccine during study or within 5 months after final dose of nivolumab and relatlimab
  14. Patients with prior, unrelated requiring current active treatment with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin or other malignancies with no evidence of disease for 2 years or more
  15. Major surgical procedure, other than for diagnosis, within 4 weeks prior to registration
  16. History of idiopathic pulmonary fibrosis, organising pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis Note: History of radiation pneumonitis in the radiation field (fibrosis) is permitted
  17. Patient is pregnant or breastfeeding/chestfeeding
  18. Prior allogeneic stem cell or solid organ transplantation
  19. Known allergy or sensitivity nivolumab, relatlimab, temozolomide or their
  20. Patient has any kind of disorder that, in the opinion of the site PI, may compromise the ability of the patient to give written and/or to comply with all required study procedures
  21. Patients with a history of myocarditis
  22. Patient has troponin T (TnT) or I (TnI) > 2 × Note: Patients with TnT or TnI levels between > 1 × to 2 × ULN will be eligible if repeat levels within 24 hours are ≤ 1 × ULN. If TnT or TnI levels are between > 1 × to 2 × ULN within 24 hours, the patient must be evaluated by a cardiologist. When repeat levels within 24 hours are not available, a repeat test should be conducted as soon as possible. If TnT or TnI repeat levels beyond 24 hours are \< 2 × ULN, the patient must be evaluated by a cardiologist. After cardiologist evaluation, the patient may be eligible if the site PI assesses a favorable benefit/risk
  23. (LVEF) \< 50% by either echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 6 months prior to registration
  24. History or evidence of any other disorder, condition, or disease (with the exception of those outlined above) that, in the opinion of the site PI would pose a risk to patient safety or interfere with the study evaluation, procedures or completion
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
92 participants (estimated)

Study arms

  • Experimental
    Nivolumab

    4 stages of treatment on Arm 1 are: 1. Neoadjuvant Treatment: Patient will receive a single dose of 480 mg by IV infusion on Day 1. 2. Resection 3. Part 1 Adjuvant Treatment: Patient will receive 480 mg of nivolumab and 380 mg of relatimab for up to 12 cycles with concomitant radiation 2Gy/day (60 Gy in total). All MGMT methylated patients under Part 1 Adjuvant Treatment setting will also receive 75 mg/m2 TMZ from Day 1 to Day 42 orally. 4. Part 2 Adjuvant Treatment: Part 1 Adjuvant Treatment will continue without concomitant radiation.

    Drug: Nivolumab · Drug: TMZ · Radiation: Radiation Therapy

  • Experimental
    Nivolumab and Relatlimab

    In Arm 2 and Safety Lead-In phase, patients will receive treatment in 4 stages as below: 1. Neoadjuvant Treatment: Patient will receive a single dose of 480 mg by IV infusion with 480 mg of relatimab on Day 1. 2. Resection 3. Part 1 Adjuvant Treatment: Patient will receive 480 mg of nivolumab and 480 mg of relatimab for up to 12 cycles with concomitant radiation 2Gy/day (60 Gy in total). All MGMT methylated patients under Part 1 Adjuvant Treatment setting will also receive 75 mg/m2 TMZ from Day 1 to Day 42 orally. 4. Part 2 Adjuvant Treatment: Part 1 Adjuvant Treatment will continue without concomitant radiation.

    Drug: Nivolumab · Drug: Relatlimab · Drug: TMZ · Radiation: Radiation Therapy

Interventions

  • For Neoadjuvant treatment, on both Arms 1 and 2, all 92 patients will receive single dose of 480 mg by IV infusion on Day 1 followed by surgery. Post-resection, in Part 1 Adjuvant treatment, all patients will receive two doses of 480 mg of nivolumab by IV infusion on Days 1 and 29. In Part 2 Adjuvant Treatment of Nivolumab dosing will continue for up to 12 cycles. Each cycle is 28 Days long.

  • For Neoadjuvant treatment, only on Arm 2, 69 patients will receive a single dose of 480 mg of nivolumab and 480 mg of relatimab by IV infusions on Day 1 followed by surgery. Post resection in Part 1 Adjuvant treatment, all patients will receive two doses of 480 mg of nivolumab and relatlimab by IV infusion on Days 1 and 29. In Part 2 Adjuvant Treatment of Relatimab dosing will continue for up to 12 cycles. Each cycle is 28 Days long.

  • DrugTemozolomideStudies of TemozolomideTemozolomide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All patients in safety lead-in, Arm 1 and Arm 2 post resection in Part 1 Adjuvant Treatment setting will receive 75 mg/m2 TMZ from Day 1 to Day 42 orally. In Part 2 Adjuvant Treatment of TMZ dosing with TMZ will continue for up to 6 cycles with 150 mg/m2 for cycle 3 and escalating to 200 mg/m2 for cycles 4 to 8 day 1 to 5 for these 6 cycles.

  • RadiationRadiation Therapy

    All patients in safety lead-in, Arm 1 and Arm 2 post resection in Part 1 Adjuvant Treatment will receive External Beam Radiation 2 Gy/day (60 Gy in total) Once daily, 5 days per week, for 6 weeks Starting on Day 1

06

What researchers measure

Primary outcomes

  1. Assess the safety of concomitantly administering nivolumab, relatlimab, RT, and TMZ in MGMT methylated patients by monitoring adverse events utilizing CTC Version 5.0 criteria

    Proportion of patients with MGMT methylation who experience an unacceptable toxicity during concomitant nivolumab, relatlimab, RT and TMZ by assessing adverse events reported utilizing CTC Version 5.0 criteria

    Time frame: From date of registration up to 4 weeks

  2. Assess the feasibility of undertaking a peri-operative study of nivolumab with or without relatlimab in patients with ndGBM (Newly diagnosed Glioblastoma)

    Proportion of registered patients who undergo biopsy, receive one cycle of randomized neoadjuvant immunotherapy, and undergo surgery during the neoadjuvant phase of the study, OR undergo biopsy that documents the patient to not have GBM. Proportion of randomized patients who receive one cycle of randomized neoadjuvant immunotherapy, and undergo surgery.

    Time frame: From date of registration up to 4 weeks

  3. Establish the biological activity of nivolumab with or without relatlimab in patients with ndGBM by demonstrating the presence of Tumor-infiltrating lymphocytes (TILs) in the resected tumor

    Changes in TILs in formalin-fixed paraffin embedded (FFPE) tumor sections from biopsy to resection during concomitant nivolumab, relatlimab, RT and TMZ

    Time frame: From date of registration up to 2 years

Secondary outcomes

  1. Describe the toxicity of nivolumab with or without relatlimab in patients with ndGBM following biopsy, and prior to surgery

    Proportion of patients who experience Grade 3+ toxicity during neoadjuvant treatment that is attributable to nivolumab and/or relatlimab utilizing CTC Ver 5.0 to assess toxicity

    Time frame: From date of registration up to 2 years

  2. Assess the safety of planned craniotomy and resection after stereotactic biopsy and treatment with nivolumab with or without relatlimab in patients with ndGBM

    30-day morbidity post biopsy or post resection

    Time frame: From date of registration up to 4 weeks

  3. Assess the safety of nivolumab and relatlimab in combination with standard of care chemoradiation in patients with ndGBM.

    Proportion of patients who experience Grade 3+ toxicity during post-surgery treatment that is attributed to nivolumab and/or relatlimab utilizing CTC Ver 5.0 to assess toxicity

    Time frame: From date of registration up to 2 years

  4. Determine the radiological response to nivolumab with or without relatlimab in ndGBM

    Proportion of patients within each arm with a CR or PR per RANO 2.0 criteria

    Time frame: From date of registration up to 2 years

  5. Describe Overall Survival (OS) and Progression Free Survival (PFS) of patients who have been randomized or assigned (as in the Stage 1 safety lead-in) or randomized (Stage 2) to receive neoadjuvant nivolumab administered with or without relatlimab

    Median OS and median PFS

    Time frame: From date of registration up to 2 years

  6. Assess the safety of planned craniotomy and resection after stereotactic biopsy and treatment with nivolumab with or without relatlimab in patients with ndGBM

    30-day mortality post biopsy or post resection

    Time frame: From date of registration up to 4 weeks

  7. Assess the safety of planned craniotomy and resection after stereotactic biopsy and treatment with nivolumab with or without relatlimab in patients with ndGBM

    Number of days delay until biopsy or resection

    Time frame: From date of registration up to biopsy or resection

  8. Assess the safety of planned craniotomy and resection after stereotactic biopsy and treatment with nivolumab with or without relatlimab in patients with ndGBM

    Number of subsequent resections

    Time frame: From date of registration up to 4 weeks

07

Study locations

4 of 4 sites recruiting
08

References and documents

Publications

  • Long GV, Shklovskaya E, Satgunaseelan L, Mao Y, da Silva IP, Perry KA, Diefenbach RJ, Gide TN, Shivalingam B, Buckland ME, Gonzalez M, Caixeiro N, Vergara IA, Bai X, Rawson RV, Hsiao E, Palendira U, Phan TG, Menzies AM, Carlino MS, Quek C, Grimmond SM, Vissers JHA, Yeo D, Rasko JEJ, Khasraw M, Neyns B, Reardon DA, Ashley DM, Wheeler H, Back M, Scolyer RA, Drummond J, Wilmott JS, Rizos H. Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma. Nat Med. 2025 May;31(5):1557-1566. doi: 10.1038/s41591-025-03512-1. Epub 2025 Feb 27. PubMed 40016450 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jun 2029, 42 months after the start.

Of 197 non-industry phase 2 interventional studies under Glioblastoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 42 months is below that.

Counting every sponsor, half of 248 studies reached it within 55 months; a quarter within 40 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2024
First posted
Feb 10, 2025
StartActual
Nov 28, 2025
Primary completionEst.
Jun 1, 2029
CompletionEst.
Jun 1, 2031
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06816927
Lead sponsor
Duke University
Responsible party
Mustafa Khasraw, MBChB, MD, FRCP, FRACP (Professor of Neurosurgery • Neuro Oncology, Duke University) — Principal investigator
First posted
Feb 10, 2025
Start date
Nov 28, 2025
Primary completion
Jun 1, 2029 (estimated)
Completion
Jun 1, 2031 (estimated)
Last update
Sep 17, 2026

Study contacts

Mustafa Khasraw
Contact
mustafa.khasraw@duke.edu
9196845301
Brain Intake office
Contact
dukebrain1@duke.edu
919-684-5301

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion